Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05963594
Other study ID # 22.06.CLI
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 23, 2023
Est. completion date March 28, 2023

Study information

Verified date July 2023
Source Société des Produits Nestlé (SPN)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this mechanistic, exploratory study is to compare the effectiveness of Oligomalt to Glucidex 40 after eating in adults with Type 2 Diabetes (T2D) and in otherwise healthy adults with overweight or obesity (HAO).


Description:

The main question it aims to answer is how consumption of Oligomalt, a slowly digestible carbohydrate, will reduce glucose and insulin spikes in adults with T2D and in HAO relative to Glucidex 40.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date March 28, 2023
Est. primary completion date March 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Type 2 Diabetes (T2D) Inclusion criteria: 1. Willing and able to sign written informed consent prior to study entry. 2. Male or female, >18 years of age. 3. Established diagnosis of T2D (documented by either HbA1c 6.5 - 10.0% or a history of T2D diagnosis). 4. Treatment naïve or on active therapy with metformin at a daily dose of 1000-3000 mg at screening. Dose of metformin must have been stable for at least 3 months prior to screening. 5. Participants must have a hematocrit value greater than or equal to 34.0% for females and 40% for males. 6. Participants must have a hemoglobin value greater than or equal to 11.0 g/dL for females and 13.5 g/dL for males. Exclusion Criteria: 1. Type 1 diabetes. 2. Known food allergy or intolerance to study products. 3. Major medical/surgical event in the last 3 months potentially interfering with study procedures and assessments. 4. Abnormal bowel transit, history of a gastrointestinal disorder (e.g., inflammatory bowel disease, diverticular diseases, colon cancer), or history of chronic constipation with passage of fewer than 3 spontaneous bowel movements per week on average or chronic or recurrent diarrhea with spontaneous bowel movements more often than 3 times daily. 5. Any concomitant medication potentially interfering with study procedures and assessment: such as antibiotics, antiacids, or other medications impacting transit time, colonoscopy, irrigoscopy or other bowel cleansing procedures 4 weeks prior to dosing. 6. Current use of injectable insulin therapy, any other oral (other than metformin) or injectable glucose-lowering drug. Current use of weight loss interventions or treatment with anorectic drugs (e.g., GLP-1 receptor analogues). 7. Current treatment with anticoagulants or antithrombotic agents (warfarin, NOACs, heparin, platelet inhibitors). 8. Current treatment with systemic steroids (application of inhaled or topical steroids is permitted). 9. Recent episode of an acute gastrointestinal illness. 10. Alcohol intake higher than 2 servings per day. A serving is 0.4 dl/1.41 ounces of strong alcohols, 1 dl/3.5 ounces of red or white wine, or 3 dl/10.6 ounces of beer. 11. Current daily cigarette smoking. 12. Are unable to comply with protocol procedures in the opinion of the investigator. 13. Have a hierarchical link with the research team members. 14. Positive pregnancy test or breast-feeding at screening. 15. Participants who have been dosed in another clinical study with any investigational drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to screening. 16. Donation of blood or significant amount of blood loss within 8 weeks prior to screening. Participants must also agree to not donate blood within 8 weeks after their last visit. HAO: Otherwise Healthy Adults (HAO) with overweight or obese but who DO NOT present with a confirmed diagnosis of diabetes mellitus Inclusion criteria: 1. Willing and able to sign written informed consent prior to study entry. 2. Male or female, >18 years of age. 3. BMI = 25 kg/m2. 4. Fasting plasma glucose (FPG) = 125 mg/dL. Exclusion criteria: 1. Type 1 or type 2 diabetes (including those potentially detected at screening). 2. 2-h plasma glucose = 200 mg/dL - if measured within 6 weeks prior to screening. 3. Known food allergy or intolerance to study products. 4. Major medical/surgical event in the last 3 months potentially interfering with study procedures and assessments. 5. Abnormal bowel transit, history of a gastrointestinal disorder (e.g., inflammatory bowel disease, diverticular diseases, colon cancer), or history of chronic constipation with passage of fewer than 3 spontaneous bowel movements per week on average or chronic or recurrent diarrhea with spontaneous bowel movements more often than 3 times daily. 6. Any concomitant medication potentially interfering with study procedures and assessment: such as antibiotics, antiacids, or other medications impacting transit time, colonoscopy, irrigoscopy or other bowel cleansing procedures four weeks prior to dosing. 7. Current use of injectable insulin therapy, any oral or injectable glucose-lowering drug. 8. Current use of weight loss interventions or treatment with anorectic drugs (e.g., GLP-1 receptor analogues). 9. Current treatment with anticoagulants or antithrombotic agents (warfarin, NOACs, heparin, platelet inhibitors). 10. Current treatment with systemic steroids (application of inhaled or topical steroids is permitted). 11. Recent episode of an acute gastrointestinal illness. 12. Alcohol intake higher than 2 servings per day. A serving is 0.4 dl/1.41 ounces of strong alcohols, 1 dl/3.5 ounces of red or white wine, or 3 dl/10.6 ounces of beer. 13. Current daily cigarette smoking. 14. Are unable to comply with protocol procedures in the opinion of the investigator. 15. Positive pregnancy test or breast-feeding at screening. 16. Participants who have been dosed in another clinical study with any investigational drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to screening. 17. Donation of blood or significant amount of blood loss within 8 weeks prior to screening. Participants must also agree to not donate blood within 8 weeks after their last visit.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Oligomalt
The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
maltodextrin
The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Locations

Country Name City State
United States Orange County Research Center Tustin California

Sponsors (1)

Lead Sponsor Collaborator
Société des Produits Nestlé (SPN)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Plasma glucose at individual timepoints Over the course of 3 hours following study product intake
Other Between-group comparison of changes in glucose slope From the time point at which maximum glucose level is measured to 3 hours
Other Between group comparison of mean "Interquartile range" IQR is defined as the difference between mean Q1 and mean Q3 glucose levels (mmol/L) Over the course of 3 hours following study product intake
Other Serum insulin at individual timepoints Over the course of 3 hours following study product intake
Other Plasma glucagon-like peptide 1 (GLP-1) at individual timepoints Over the course of 2 hours following study product intake
Other Plasma peptide tyrosine (PYY) at individual timepoints Over the course of 2 hours following study product intake
Other Plasma glucagon-like peptide 1 (GLP-1) Over the course of 1 hour following study product intake
Other Plasma peptide tyrosine (PYY) Over the course of 1 hour following study product intake
Primary Incremental area under the curve (iAUC) of post-prandial glycemic excursion induced by Oligomalt relative to maltodextrin over the observation period: iAUC 0-1 hour, iAUC 0-2 hours, iAUC 0-3 hours. Comparisons in the T2D group: 50 g Oligomalt vs 50 g Glucidex 40. Comparisons in the HAO group: 33 g Oligomalt vs 33 g Glucidex 40 and 50 g Oligomalt vs 50 g Glucidex 40. Over the course of 3 hours following study product intake
Secondary Total blood glucose AUC Over the course of 3 hours following study product intake
Secondary Blood glucose (iCmax) Maximum blood glucose level Over the course of 3 hours following study product intake
Secondary Blood glucose (Cmin) Minimum blood glucose level Over the course of 3 hours following study product intake
Secondary Blood glucose (Tmax) Time point at which maximum blood glucose level is measured Over the course of 3 hours following study product intake
Secondary Blood glucose (Tmin) Time point at which minimum blood glucose level is measured Over the course of 3 hours following study product intake
Secondary Number of participants with glucose levels less than or equal to 3.9 mmol/L Over the course of 3 hours following study product intake
Secondary Number of participants with glucose levels less than or equal to 3.1 mmol/L Over the course of 3 hours following study product intake
Secondary Serum insulin level Over the course of 3 hours following study product intake
Secondary Insulinogenic index (IGI) A measure of early ß-cell capacity (first- phase insulin response) 30 minutes
Secondary Insulin index Over the course of 2 hours following study product intake
Secondary Matsuda Index (MI) Over the course of 2 hours following study product intake
Secondary Plasma glucagon-like peptide 1 (GLP-1) Over the course of up to 3 hours following study product intake
Secondary Plasma peptide tyrosine (PYY) Over the course of up to 3 hours following study product intake
See also
  Status Clinical Trial Phase
Completed NCT04639726 - A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response. N/A
Recruiting NCT05738746 - The Efficacy of Pasteurised Akkermansia Muciniphila in Healthy Medical Workers N/A
Completed NCT01462058 - The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff Phase 4
Completed NCT05210244 - Acute Beetroot Juice Supplementation in Amateur Climbers N/A
Not yet recruiting NCT06433310 - Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study Early Phase 1
Completed NCT05337527 - Neuromuscular Responses to Acute Beetroot Ingestion in Women Older Adults N/A
Active, not recruiting NCT04429737 - The Effects of Freshwater Clam Extract on Blood Sugar, and Lipid Profile in Prediabetes Patients N/A
Completed NCT04210531 - Beetroot Juice Supplementation in Basketball Players N/A
Recruiting NCT05941949 - Nutritional Supplement's Effects on Cognition N/A
Completed NCT04877366 - Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia N/A
Recruiting NCT03998306 - Probiotics in Children With Early Childhood Caries N/A
Completed NCT05984771 - Efficacy and Safety of the Combination of Ten Elements for 6 Months in Patients With Diabetic Neuropathy : A Pilot Study N/A
Completed NCT05880186 - Influence of the Time of Day in the Effect of Caffeine on Maximal Fat Oxidation During Exercise in Women N/A
Completed NCT03418376 - Carnosine Loading and Periodized Training in MS and HC N/A
Completed NCT03395119 - Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects Phase 1
Completed NCT04761406 - Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management N/A
Completed NCT04832412 - Effect of BrainPhyt, a Microalgae Based Ingredient on Cognitive Function in Healthy Older Subjects N/A
Recruiting NCT04438486 - Effects of Barley Green in Patients With Hyperuricemia N/A